MeMed Diagnostics
5 Nahum Het Street
Tirat Carmel
39120
Tel: 972-4-8500302
Fax: 972-4-8500298
Website: http://www.me-med.com/
Email: info@me-med.com
About MeMed Diagnostics
MeMed is dedicated to improving patient lives through research, development, and commercialization of pioneering products that decode the immune system's distinct responses to different health and disease states. The company's most advanced product, ImmunoXpert™, accurately detects whether a patient has a bacterial or viral infection, with the aim of empowering physicians to make better informed antibiotic treatment decisions. ImmunoXpert™ is CE marked and approved for clinical use in the EU, Switzerland, and Israel.YEAR FOUNDED:
2009
LEADERSHIP:
Founder and CEO: Eran Eden, PhD
Founder and CTO: Kfir Oved, PhD, MD
CCO: Patrick F. Terry
JOBS:
Please click here for MeMed job opportunities.
FOLLOW MEMED:
Tweets by MeMed
12 articles about MeMed Diagnostics
-
MeMed Bolsters Leadership Team With Appointment of Ori Hadomi as Chairman and Peter Scheu as President of MeMed US
11/6/2023
MeMed announces the appointment of Mr. Ori Hadomi as Chairman of the Board of Directors and Mr. Peter Scheu, as President of MeMed US.
-
MeMed awarded US BARDA contract to demonstrate clinical utility of the FDA-cleared MeMed BV® test for distinguishing bacterial from viral infections
10/24/2023
MeMed is pleased to announce that it has been awarded a contract valued at $727,799 by the Division of Research, Innovation, and Ventures of the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority.
-
MeMed: FDA Clears Pioneering MeMed BV Test Direct From Whole Blood Allowing Faster Time To Result And Broader Patient Access When Distinguishing Bacterial From Viral Infections
7/19/2023
MeMed, a leader in the emerging field of advanced host response technologies, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for use of the MeMed BV® test on whole blood samples on the point-of-need MeMed Key® analyzer to help healthcare providers distinguish between bacterial and viral infections in 15 minutes.
-
MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio
1/10/2022
MeMed, a leader in host response technologies, announces a $93 million private financing round, bringing total funding in the Company to over $200 million, including support from the U.S. Department of Defense and EU Commission.
-
Diagnostics Industry Veteran Dr. Frédéric Sweeney Joins MeMed as Chief Business Development Officer
10/29/2019
MeMed Ltd., a leader in host response-based diagnostic solutions, announced the addition of Dr. Frédéric Sweeney to its executive team as Chief Business Development Officer.
-
MeMed Named "Technology Pioneer" by World Economic Forum
7/1/2019
Company Recognized for Novel Solution to Combat Growing Threat of Antibiotic Resistance
-
MeMed Raises Over $70 Million to Advance Pioneering Point-Of-Care Platform and Immune-Based Test for Distinguishing Bacterial Versus Viral Infections
9/20/2018
MeMed today announced the completion of a new round of financing totaling over $70 million, with participation from new and existing investors including Ping An Global Voyager Fund, Foxconn, Caesarea Medical Holdings, Clal Insurance, Phoenix Insurance, OurCrowd, Social Capital, WTI, Horizons Ventures, and high-net-worth executives renowned for early investments in industry-changing companies.
-
MeMed Diagnostics Completes Trilogy Of Clinical Studies With More Than 2,000 Patients Validating First Ever Blood Test To Accurately Distinguish Between Bacterial And Viral Infections
9/18/2017
-
MeMed Diagnostics Awarded $9.2M Contract By U.S. Department Of Defense
4/19/2017
-
MeMed Diagnostics Awarded $9.2M Contract By U.S. Department Of Defense
4/19/2017
-
Lancet Infectious Diseases Publishes Independent Double-Blind Study Validating MeMed Diagnostics's Immunoxpert Blood Test's Ability To Accurately Distinguish Between Bacterial And Viral Infections In Children
12/22/2016
-
MeMed Diagnostics Release: €2.3 Million Award By European Commission (EC) Will Support Deployment Of Immunoxpert To Reduce Antibiotic Misuse In Hospitals
9/8/2016